What the label lists and what reports show
Angiotensin ii side effects
Angiotensin ii's FDA label: “The most common adverse reactions reported in greater than 10% of GIAPREZA treated patients were thromboembolic events.” FAERS holds 297 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is acute kidney injury (25 reports).
- Generic listed
Check it at the source: the angiotensin ii FDA label on DailyMed (effective July 22, 2026, La Jolla Pharmaceutical Company); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsThe most common adverse reactions reported in greater than 10% of GIAPREZA treated patients were thromboembolic events.
Table 1: Adverse Reactions Occurring in ≥ 4% of Patients Treated with GIAPREZA and ≥ 1.5% More Often than in Placebo-treated Patients in ATHOS-3
| Adverse Event | GIAPREZA N=163 | Placebo N=158 |
|---|---|---|
| Thromboembolic events Including arterial and venous thrombotic events | 21 (12.9%) | 8 (5.1%) |
| Deep vein thrombosis | 7 (4.3%) | 0 (0.0%) |
| Thrombocytopenia | 16 (9.8%) | 11 (7.0%) |
| Tachycardia | 14 (8.6%) | 9 (5.7%) |
| Fungal infection | 10 (6.1%) | 2 (1.3%) |
| Delirium | 9 (5.5%) | 1 (0.6%) |
| Acidosis | 9 (5.5%) | 1 (0.6%) |
| Hyperglycemia | 7 (4.3%) | 4 (2.5%) |
| Peripheral ischemia | 7 (4.3%) | 4 (2.5%) |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedADVERSE REACTIONS The most common adverse reactions reported in greater than 10% of GIAPREZA treated patients were thromboembolic events. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact La Jolla Pharmaceutical Company at 1-800-651-3861 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ATHOS-3 The safety of GIAPREZA was evaluated in ATHOS-3 [see Warnings and Precautions(5.1) ]. Patients in ATHOS-3 were receiving other vasopressors in addition to GIAPREZA or placebo, which were titrated to effect on mean arterial pressure (MAP). Table 1 summarizes adverse reactions with an incidence of at least 4% among patients treated with GIAPREZA and with a rate of at least 1.5% higher with GIAPREZA than with placebo. …
Source: FDA drug label, La Jolla Pharmaceutical Company, effective July 22, 2026 (SPL set c265d69a-3efe-4107-9a9e-e6fd3d531c48), via openFDA; the full label on DailyMed
What do FAERS reports show?
297 reports list angiotensin ii among the medicines taken, each a report of something that happened, not proof the medicine caused it; 94 are coded as a death and 116 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 16 reactions below, 3 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Angiotensin ii: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions